Lu Chongmao, director of the Hong Kong Medical and Health Bureau, said that the important experience of the Hong Kong Government's harvest from the three -year crown disease, that is, must accelerate Hong Kong's drug research and development capabilities. Therefore, the official is considering establishing a similar American food and drug management in Hong Kong.The regulatory agency of the bureau (FDA) hopes to attract pharmaceutical companies to invest in Hong Kong to invest in research and development.
Lu Chongmao made the above statements in an exclusive interview with the Hong Kong South China Morning Post on Wednesday (June 28).The interview was published on Friday (30th).
Lu Chongmao said in an exclusive interview that the three -year crown disease caused him to deeply feel that Hong Kong needs to strengthen its research and development capabilities.Although the University of Hong Kong has outstanding scientific research capabilities, there is a gap in clinical testing and approval.
Under the current drug approval system of Hong Kong, drugs must be permitted by two or more foreign regulatory agencies before applying for approval permits in Hong Kong.Lu Chongmao believes that this move is too passive and it is difficult to attract foreign pharmaceutical factories to settle in Hong Kong to invest in research and development.
Lu Chongmao said that he noticed that the location of the drug research and development and approval was often closely linked (Closly Linked).Approval of drug application.
He believes that doing so can speed up drug approval and cooperate with the huge market in mainland China. It is expected that more foreign pharmaceutical plants can invest in Hong Kong to invest in research and development and conduct clinical trials, which will help improve Hong Kong as a regional biomedical centerThe status."Foreign drugs and the most advanced medical products can also introduce the Greater Bay Area market."The factory conducts research or clinical trials in Hong Kong, which can make the second or third phase of the Phase III through the population of the Greater Bay Area.If you study carefully, you hope to set up a set of standards.
The Hong Kong pharmaceutical community welcomes the concept of the Hong Kong Government.According to a report on Friday, Hong Kong Zhongtong News Agency, Liang Runsong, a professor at the Department of Applied Biology and Chemical Science and Technology of the University of Technology in Hong Kong, said that the establishment of a drug approval agency in Hong Kong will benefit from accelerating the approval process and help to promote drug development and drug testing.Hong Kong is an international city. It is believed that Hong Kong's clinical test has been recognized internationally and helps drugs into the international market.
Cui Junming, president of the Society of Pharmacist Society of the Hong Kong Hospital, pointed out that many new drug research and development in mainland China cooperate with foreign pharmaceutical factories.Longer.If Hong Kong can be approved, new drug supply will be increased and the price of drugs will be reduced.
